Updated from 12:58 p.m. EDT
was one of Monday's best performers. On Friday, the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. A final decision from the FDA is expected on May 15. Shares of Dendreon, which soared 147% on Friday, closed up $1.37, or 10.6%, to $14.30.
jumped 17.8% after the company said its vaccine prevention for H9N2, another strain of the avian flu virus, was effective when tested on animals. Shares of Novavax gained 46 cents to $3.05.
were also higher after Jefferies upgraded the stock to buy from hold. The firm also upped Cephalon's stock price target to $88 from $69. The stock climbed $4.75, or 6.7%, to $75.96.
On the other hand,
was losing ground after Bear Stearns lowered its rating on the company to underperform from peer perform. Shares of Bruker were recently down 26 cents, or 2.5%, to $10.26.
Among other health care winners,
added 2.6% to $53.80.
was gaining 1.8% to $73.84.
was higher by 1.9% at $45.01.
shed 4.5% to $7.62.
was off 2.2% to $35.60, and
was lower by 0.4% at $25.42.